Pearson plc (PSO)
NYSE: PSO · Real-Time Price · USD
15.74
-0.09 (-0.57%)
At close: Apr 23, 2025, 4:00 PM
15.77
+0.03 (0.19%)
Pre-market: Apr 24, 2025, 7:39 AM EDT
Pearson Revenue
In the year 2024, Pearson had annual revenue of 3.55B GBP, down -3.32%. Pearson had revenue of 1.80B in the half year ending December 31, 2024, a decrease of -12.42%.
Revenue (ttm)
3.55B GBP
Revenue Growth
-3.32%
P/S Ratio
2.31
Revenue / Employee
208,647 GBP
Employees
17,024
Market Cap
10.28B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55B | -122.00M | -3.32% |
Dec 31, 2023 | 3.67B | -167.00M | -4.35% |
Dec 31, 2022 | 3.84B | 413.00M | 12.05% |
Dec 31, 2021 | 3.43B | 31.00M | 0.91% |
Dec 31, 2020 | 3.40B | -472.00M | -12.20% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alphabet | 350.02B |
Meta Platforms | 164.50B |
Verizon Communications | 135.29B |
Comcast | 123.73B |
AT&T Inc. | 122.93B |
The Walt Disney Company | 92.50B |
T-Mobile US | 81.40B |
Netflix | 40.17B |
PSO News
- 1 day ago - New Pearson research: The New AI talent strategy is redesigning roles - PRNewsWire
- 14 days ago - Certifications Fuel Success in the Age of AI: Pearson Releases the 2025 Value of IT Certification Candidate Report - PRNewsWire
- 16 days ago - Pearson Redefines its Brand to Embrace the Future of Learning - PRNewsWire
- 21 days ago - Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome - GlobeNewsWire
- 22 days ago - ExtensisHR's David R. Pearson Honored as CHRO of the Year by C-Suite Insider - Business Wire
- 23 days ago - Pearson Announces Newly Expanded Role for Chief Technology Officer, Dave Treat, as Company Further Scales AI and Tech Capabilities - PRNewsWire
- 24 days ago - Pearson Expands Professional Learning Capabilities with New Skilling Partner Program - PRNewsWire
- 6 weeks ago - Pearson Announces Arden Hoffman as Non-Executive Director - PRNewsWire